Alzheimer's Disease Trial, Not Yet Recruiting NCT07166744 Sponsor: University Hospital, Strasbourg, France Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07166744
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 50 or older, male or female, who show signs of one of the following conditions: Lewy body disease (a brain condition affecting thinking and movement), diagnosed using recognised medical guidelines and supported by specific brain scans and other tests where needed.
  • People diagnosed with Alzheimer's disease, identified using recognised medical guidelines.
  • People showing signs of both Lewy body disease and Alzheimer's disease, confirmed through relevant brain scans and diagnostic guidelines.
  • People with a type of brain disease affecting the front and side areas of the brain (fronto-temporal disease), which may include conditions such as fronto-temporal dementia, cortico-basal degeneration, supranuclear palsy, or a condition called LATE — all identified using recognised medical guidelines.
  • People with a psychiatric condition such as depression, bipolar disorder, or schizophrenia, diagnosed according to standard medical guidelines (DSM-5).
  • People who are accompanied by a carer or someone who can provide information about them, in cases where the treating doctor believes the patient cannot provide this information on their own.
  • People who are able to understand the aims and risks of the research and can give their signed, dated consent — or whose legal representative or guardian can provide consent on their behalf.
  • People who are covered by a social health insurance scheme.
  • People who are experiencing either mild memory and thinking difficulties, or mild to severe dementia, based on standard cognitive assessment scores (MMSE score between 5 and 30).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have another neurological condition not related to the study, such as a brain tumour, stroke with cognitive impairment, or multisystem atrophy, as determined by the treating doctor.
  • People for whom a lumbar puncture (a procedure to collect fluid from the spine) is not medically safe.
  • People for whom a brain MRI scan is not medically safe (this applies only to participants at the Strasbourg site).
  • People for whom it would not be possible to stay in contact with the study team for the full duration of the trial, for example due to a planned move.
  • People under a specific French legal protection measure called "sauvegarde de justice."
  • People in an emergency or life-threatening situation where it is not possible to properly inform them about the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 January 2032

Primary endpoints

Evaluation of the diagnostic value of pathological α-synuclein in cerebrospinal fluid (CSF) using lumbar puncture.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov